Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
Alcohol use and metabolic syndrome are highly prevalent in the population and frequently co-exist. Both are implicated in a large range of health problems, including chronic liver disease, hepatocellular carcinoma, and liver-related outcomes (i.e. decompensation or liver transplantation). Studies have yielded mixed results regarding the effects of mild-moderate alcohol consumption on the risk of metabolic syndrome and fatty liver disease, possibly due to methodological differences. The few available prospective studies have indicated that mild-moderate alcohol use is associated with an increase in liver-related outcomes. This conclusion was substantiated by systems biology analyses suggesting that alcohol and metabolic syndrome may play a similar role in fatty liver disease, potentiating an already existing dysregulation of common vital homeostatic pathways. Alcohol and metabolic factors are independently and jointly associated with liver-related outcomes. Indeed, metabolic syndrome increases the risk of liver-related outcomes, regardless of alcohol intake. Moreover, the components of metabolic syndrome appear to have additive effects when it comes to the risk of liver-related outcomes. A number of population studies have implied that measures of central/abdominal obesity, such as the waist-to-hip ratio, can predict liver-related outcomes more accurately than BMI, including in individuals who consume harmful quantities of alcohol. Many studies even point to synergistic interactions between harmful alcohol use and many metabolic components. This accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease highlights the multifactorial background of liver disease in the population. The available evidence suggests that more holistic approaches could be useful for risk prediction, diagnostics and treatment planning.
NAFLD, alcohol use, cardiovascular disease, hepatocellular carcinoma, liver disease, metabolic syndrome
191-206
Åberg, Fredrik
f2b4e91d-14bb-499f-bfed-5dd4b25d1d66
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Pirola, Carlos J
abec69d7-1ed0-46e9-bdc6-99f6a5a8349c
Männistö, Ville
af723dfd-1c1f-4891-b978-07d7cfdf32da
Sookoian, Silvia
e9b2201c-e768-47c6-8927-be0c525b4d7f
5 September 2022
Åberg, Fredrik
f2b4e91d-14bb-499f-bfed-5dd4b25d1d66
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Pirola, Carlos J
abec69d7-1ed0-46e9-bdc6-99f6a5a8349c
Männistö, Ville
af723dfd-1c1f-4891-b978-07d7cfdf32da
Sookoian, Silvia
e9b2201c-e768-47c6-8927-be0c525b4d7f
Åberg, Fredrik, Byrne, Christopher, Pirola, Carlos J, Männistö, Ville and Sookoian, Silvia
(2022)
Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease.
Journal of Hepatology, 78 (1), .
(doi:10.1016/j.jhep.2022.08.030).
Abstract
Alcohol use and metabolic syndrome are highly prevalent in the population and frequently co-exist. Both are implicated in a large range of health problems, including chronic liver disease, hepatocellular carcinoma, and liver-related outcomes (i.e. decompensation or liver transplantation). Studies have yielded mixed results regarding the effects of mild-moderate alcohol consumption on the risk of metabolic syndrome and fatty liver disease, possibly due to methodological differences. The few available prospective studies have indicated that mild-moderate alcohol use is associated with an increase in liver-related outcomes. This conclusion was substantiated by systems biology analyses suggesting that alcohol and metabolic syndrome may play a similar role in fatty liver disease, potentiating an already existing dysregulation of common vital homeostatic pathways. Alcohol and metabolic factors are independently and jointly associated with liver-related outcomes. Indeed, metabolic syndrome increases the risk of liver-related outcomes, regardless of alcohol intake. Moreover, the components of metabolic syndrome appear to have additive effects when it comes to the risk of liver-related outcomes. A number of population studies have implied that measures of central/abdominal obesity, such as the waist-to-hip ratio, can predict liver-related outcomes more accurately than BMI, including in individuals who consume harmful quantities of alcohol. Many studies even point to synergistic interactions between harmful alcohol use and many metabolic components. This accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease highlights the multifactorial background of liver disease in the population. The available evidence suggests that more holistic approaches could be useful for risk prediction, diagnostics and treatment planning.
Text
JHep_reviewREVISED_CLEAN2
- Accepted Manuscript
Text
Supplementary Appendix 300522
- Accepted Manuscript
Text
Figures
- Accepted Manuscript
Text
1-s2.0-S0168827822030616-main
- Proof
More information
Accepted/In Press date: 22 August 2022
e-pub ahead of print date: 5 September 2022
Published date: 5 September 2022
Keywords:
NAFLD, alcohol use, cardiovascular disease, hepatocellular carcinoma, liver disease, metabolic syndrome
Identifiers
Local EPrints ID: 469711
URI: http://eprints.soton.ac.uk/id/eprint/469711
ISSN: 0168-8278
PURE UUID: 3e24ea2e-92ca-4537-af8b-eb3826350f95
Catalogue record
Date deposited: 22 Sep 2022 16:47
Last modified: 17 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
Fredrik Åberg
Author:
Carlos J Pirola
Author:
Ville Männistö
Author:
Silvia Sookoian
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
